Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations
This facility manufactures APIs & formulations of oncology and non-oncology products.
This facility manufactures APIs & formulations of oncology and non-oncology products.
Sun Pharma's Dadra facility receives OAI status from US FDA
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Total value of the supplies of FC will be US$ 2.773 million
Fluid bed processes: drying, granulating, and coating in just one product container
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Subscribe To Our Newsletter & Stay Updated